Coherus Oncology, Inc. (CHRS) Investor Relations Documents

Coherus Oncology, Inc. (CHRS) investor relations documents from the company's IR site: 14 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-05	Press release	Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-22	Press release	Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-06-23	Press release	Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalim
2026-05-11	Press release	Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-04	Press release	Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
2026-03-09	Press release	Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
2026-03-02	Press release	Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
2026-02-23	Press release	Coherus Oncology to Participate in Upcoming Investor Conferences
2026-02-17	Press release	Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
2026-02-12	Press release	Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
2026-02-12	Press release	Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
2026-02-04	Press release	Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig
2026-01-06	Press release	Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-05	Press release	Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investig

CHRS overview · CHRS earnings · CHRS financials · CHRS KPIs · CHRS ownership · CHRS peers · CHRS filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.